Chitosan Versus Glucosamine Phonophoresis in the Management of Knee Osteoarthritis

N/AUnknownNCT05420441

October 6 University60 enrolled

Overview

The study will be conducted to answer the following questions: * Is there an effect of phonophoresis using glucosamine on pain level , function and range of motion in knee osteoarthritis patients ? * Is there an effect of phonophoresis using chitosan on pain level , function and range of motion in knee osteoarthritis patients ? * Is there a difference between the effect of phonophoresis using glucosamine and phonophoresis using chitosan on pain level , function and range of motion in knee osteoarthritis patients ?

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Knee Osteoarthritis Knee Arthritis

Interventions

Phonophoresis with chitosanDEVICE

Patients in this group will receive chitosan through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program

Phonophoresis with glucoasmineDEVICE

Patients in this group will receive glucosamine through phonophoresis plus conventional treatment. For the phonophoresis parameters: pulsed ultrasonic waves (25%) of 1 MHz frequency and 1 W/cm2 intensity applied with a 5 cm diameter transducer. The total time of ultrasound application was eight minutes.Patients will also receive conventional Physical therapy program.

Conventional Physical Therapy

Eligibility

Sex: ALLMin age: 45 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * unilateral or bilateral grade II knee osteoarthritis (clinical and imaging diagnosis X-ray). * knee pain intensity ≥ 5 on the Visual Analogue Scale (VAS) Exclusion Criteria: * Anterior Cruciate Ligament (ACL) and meniscus injury * use of oral or injected corticosteroids in the last 3 months * history of knee surgery or fracture * acute infectious synovitis or arthritis conditions * presence of malignancy * individuals with, topical lesions, contact dermatitis and history of cutaneous hypersensitivity

Locations (1)

El-Kasr El-Ainy hospital

Al Manyal, Cairo Governorate, Egypt

Outcomes

Primary Outcomes

Change in Visual Analog Scale

The visual analog scale (VAS) is a pain rating scale first used by Hayes and Patterson in 1921. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm).

Time frame: Baseline and Change from baseline pain scores at four weeks

Change in WOMAC INDEX

The WOMAC VA 3.1 Index score (WOMAC INDEX) is the sum of WOMAC A (total pain), WOMAC B (stiffness) and WOMAC C (functional impairment) subscores. The WOMAC INDEX score ranges from 0 to 2400 mm, with higher scores indicating higher disease burden.

Time frame: Baseline and Change from baseline scores at four weeks

Range of Motion at knee joint both in extension and flexion

The ROM will be measured using the Baseline 12-1056 bubble inclinometer. Patients will be in prone position and will be instructed to move their leg away from the thigh to measure extension range of motion and move the leg toward the thigh to measure flexion

Time frame: Baseline and Change from baseline scores at four weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.